Key data
| Regulation | Royal Decree 468/2026, of June 10, which modifies Royal Decree 1345/2007, of October 11 |
|---|---|
| Publication | June 11, 2026 |
| Entry into force | June 11, 2026 |
| Affected parties | Pharmacies, hospitals, drug distributors, laboratories and NHS entities |
| Category | Regulatory Changes |
| Year | 2026 |
| Modified regulation | Royal Decree 1345/2007, of October 11 (authorization, registration and dispensing of medicines for human use) |
Pharmacies, hospitals, distributors and laboratories operating with medicines financed by the National Health System have new obligations as of June 11, 2026. The Royal Decree 468/2026 modifies Royal Decree 1345/2007 to adapt the system of verification and authentication of medicines to Spanish operational reality, with changes that directly affect dispensing processes, technological integration and package traceability.
The regulation is not a minor procedural change: it redefines how different actors connect to the national verification system and expands the cases in which the unique identifier of the package can be deactivated, which has direct operational implications for distributors and special supply centers.
What does this regulation establish?
Royal Decree 468/2026 introduces three blocks of changes to the drug verification system (unique identifiers on packages), which is the mechanism that allows tracking each unit of medicine from the manufacturer to the patient:
1. New grounds for deactivating the unique identifier
Until now, the cases in which the unique identifier of a package could be deactivated were limited to certain grounds. The Royal Decree expands this list by expressly including:
- Supplies to penitentiary centers
- Supplies to storage centers of the Ministry of Defense
This means that when a distributor or laboratory supplies medicines to these centers, it can proceed to deactivate the unique identifier of the package at that moment, without needing to wait for final dispensing to the patient.
2. Redefinition of the SNSFarma Node: two differentiated pathways
The most relevant change for the sector is the explicit differentiation within the SNSFarma Node between two types of actors:
| Type of entity | Integration in SNSFarma | Main function |
|---|---|---|
| Community pharmacies | Receive data from the repository | Management of NHS reimbursement |
| Hospital pharmacy services | Integrated directly into the repository | Traceability and direct verification in the system |
This distinction has technical and operational consequences: hospitals must ensure that their information systems are prepared for direct integration, while community pharmacies will operate with a different data flow oriented toward reimbursement.
3. Interoperability between regional and national systems
The regulation expressly guarantees interoperability between regional information systems and the national drug verification system. This is especially relevant for autonomous communities with their own pharmaceutical management systems, which must ensure compatibility with the national repository.
Economic and operational impact
The regulation does not establish direct fees or economic amounts, but generates operational costs and technological investments for the affected actors:
- Hospital pharmacy services: Direct integration into the SNSFarma repository may require adaptations in hospital information systems (HIS/SIH) to guarantee the required technical connectivity.
- Distributors and laboratories: Must update their procedures for deactivating unique identifiers to include the new grounds (penitentiary centers and Ministry of Defense storage facilities), which involves reviewing internal protocols and possibly updating traceability systems.
- Autonomous communities with their own systems: The requirement for interoperability may involve additional technological developments to ensure compatibility with the national repository.
- Community pharmacies: The impact is minor in terms of technical integration, since their role in SNSFarma is oriented toward receiving data for reimbursement, but they must verify that their management systems are updated for the new data flow.
Who does it affect?
- Community pharmacies: New role in SNSFarma oriented toward reimbursement management through receipt of data from the repository.
- Hospital pharmacy services: Obligation of direct integration into the SNSFarma repository.
- Drug distributors: New grounds for deactivating the unique identifier when supplying to penitentiary centers and Ministry of Defense storage facilities.
- Manufacturing laboratories: Affected by changes in the system of verification and authentication of packages.
- Penitentiary centers: New recognized recipients in the system for deactivating the unique identifier.
- Ministry of Defense (storage centers): Expressly included as grounds for deactivating the unique identifier.
- Autonomous communities: Required to guarantee interoperability of their information systems with the national repository.
- NHS entities: Any organization that manages medicines financed by the National Health System.
Practical example
A pharmaceutical distributor receives an order of medicines financed by the NHS to supply to a penitentiary center. Before Royal Decree 468/2026, this supply could generate operational doubts about when and how to deactivate the unique identifier of the package, since penitentiary centers were not expressly contemplated as an enabled ground.
With the new regulation, the distributor can deactivate the unique identifier at the time of supply to the penitentiary center, just as it would with a pharmacy or hospital. This simplifies the traceability process, avoids incidents in the verification system and allows the medicine's lifecycle to be properly closed in the national repository.
In parallel, if that same distributor supplies to a hospital, the hospital's pharmacy service no longer operates as a passive data receiver: it is integrated directly into the SNSFarma repository, which means the hospital must have its systems prepared for that direct integration and not just for receiving information.
What should companies do now?
- Hospital pharmacy services: Review whether the hospital's information systems (HIS/SIH) are prepared for direct integration into the SNSFarma repository. If not, initiate the technical adaptation process with the software provider.
- Pharmaceutical distributors: Update internal procedures for deactivating the unique identifier to expressly include supplies to penitentiary centers and Ministry of Defense storage centers.
- Community pharmacies: Verify with the management software provider that the system is updated for the new SNSFarma data flow oriented toward reimbursement.
- Manufacturing laboratories: Review traceability and package verification protocols to ensure they contemplate the new grounds for deactivating the unique identifier.
- Autonomous communities and managers of regional systems: Audit the interoperability of their own information systems with the national repository and plan necessary adaptations.
- All actors: Consult the full text of Royal Decree 468/2026 in the BOE and, if operating in the NHS scope, evaluate with specialized advice the specific impact on dispensing and traceability processes.
Frequently asked questions
What is the unique identifier of medicines and when can it be deactivated?
The unique identifier is a code on the package of each medicine that allows verification of its authenticity and tracking of its traceability from the manufacturer to the patient. Royal Decree 468/2026 expands the grounds for deactivating this identifier, now expressly including supplies to penitentiary centers and Ministry of Defense storage centers, in addition to existing grounds.
What is the difference between how a pharmacy and a hospital operate in the new SNSFarma?
According to Royal Decree 468/2026, community pharmacies will receive data from the SNSFarma repository for management of NHS reimbursement. In contrast, hospital pharmacy services will be integrated directly into the repository, which implies a deeper technical connection and requirements for adaptation of hospital information systems.
When does Royal Decree 468/2026 enter into force?
Royal Decree 468/2026 entered into force on the same day of its publication in the BOE: June 11, 2026. There is no transitional period established in the available data, so obligations are enforceable from that date.
What must hospitals do to comply with direct integration into the SNSFarma repository?
Hospital pharmacy services must verify that their information systems (HIS/SIH) are prepared for direct integration into the SNSFarma repository, as required by Royal Decree 468/2026. If current systems do not allow this, it is necessary to initiate with the software provider the process of technical adaptation to guarantee the required connectivity.
Does this regulation affect all pharmacies or only those working with the NHS?
Royal Decree 468/2026 specifically affects actors operating with medicines financed by the NHS: pharmacies, hospitals, distributors and laboratories working in the scope of the National Health System. The regulation governs the system of verification and authentication of medicines in that specific context.
Official source
Consult complete regulation in official source
Notice: This article is merely informative in nature and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-12611